Global Cardiovascular Drug Market Research By Drug Type (Anti-Clotting Agents, Antihyperlipidemic, Calcium Channel Blockers, Renin-Angiotensin System Blockers and Other), By Disease Type (Arrhythmia, Coronary Artery Disease, Hyperlipidemia, Hypertension and Peripheral Artery Disease), and By Distribution Channel (Hospital Pharmacy, Online Pharmacy and Retail Pharmacy) Forecast Period 2022-2028
The global cardiovascular drug market is growing at a considerable CAGR of 1.2% during the forecast period. Changing life style and eating habits is one of the prime factors affecting and driving the market. Increasing pollution in the environment, rising health care expenditure among others is also estimated to be the key factors that are contributing significantly towards the growth of the market. However, high cost involvement in treatment along with strict governmental rules and regulation for approval of drug are some major factors constraints that are hindering the growth of the global cardiovascular drug market across the globe.
Further, rising spending in R&D for drug discovery by pharmaceutical companies along with diagnosis procedure adoption of genetic engineering are some of the key factors that are creating opportunities for the market. New product launches and collaboration in the market are likely to drive the growth of the global cardiovascular drug market. For instance, in July 2020, Lilly and Boehringer Ingelheim International GmbH had set forth the results related with phase 3 trial of Jardiance (empagliflozin) that had supported in reducing risks of cardiovascular diseases or hospitalization for heart failure in adults with and without diseases.
Impact of COVID-19 on the Global Cardiovascular Drug Market
The global cardiovascular drug market is hardly hit by the COVID-19 pandemic since December 2019. The COVID-19 pandemic in the major economies had disrupted the manufacturing and transportation activities. Moreover, the proper treatment was been given by physicians to patients suffering from cardiovascular diseases.
The market is segmented based on drug type, disease type and distribution channel. Based on drug type, the market is segmented into anti-clotting agents, antihyperlipidemic, calcium channel blockers, renin-angiotensin system blockers and other. By disease type, the market is segmented into arrhythmia, coronary artery disease, hyperlipidemia, hypertension and peripheral artery disease. Further, by distribution channel, market is segmented hospital pharmacy, online pharmacy and retail pharmacy.
Global Cardiovascular Drug Market Share by Drug Type 2020 (%)
Global Cardiovascular Drug Market Share by Drug Type
Based on the drug type, the anti-clotting agents segment holds a significant share in the market. It is one of the important drugs in order to manage cardiovascular diseases. These are drugs that are considered to be given to the patient for preventing the blood clots. When the patients are at high risk of getting clots this drug supports in reducing the chances of developing something serious in them.
The global cardiovascular drug market is analyzed based on the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America held a considerable share in 2020 in the global cardiovascular drug market. Some factors that are boosting the market growth in North America are increasing pervasiveness of cardiovascular diseases along with presence of the leading players in the market. Additionally, investment in health care facility in the region and adoption of genetic engineering in the US is boosting the market in this region.
Global Cardiovascular Drug Market, by Region 2022-2028
Global Cardiovascular Drug Market, by Region
Asia-Pacific will have Considerable Growth in the Global Cardiovascular Drug Market
Asia-Pacific region is expected to witness significant growth opportunities for the market. Increasing alcohol consumption along with rising changes in lifestyle in emerging economies of the region are likely to drive the growth of the regional market. Further due to rising government funding in order to improve health care infrastructure in India, China and South Korea are also some of the factors that are affecting and impacting the growth in this market.
Market Player Outlook
Key players of the global cardiovascular drug market are Daiichi Sankyo Co., Ltd., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Novartis Ag, and Merck & Co., Inc. among others. To survive in the market, these players adopt different marketing strategies such as product launches, merger and acquisition. For instance, in May 2020, Bristol-Myers Squibb Co. had announced the entering of merger agreement in which the company will acquire one of the clinical-stage bio-pharmaceutical company named as MyoKardia. Through this acquisition, the company had got the benefit of gaining mavacamten that is considered to be a cardiovascular medicine for the treatment of obstructive hypertrophic cardiomyopathy.
In December 2020, Novartis AG had received the approval from European Commission (EC) for its Leqvio (inclisiran) atherosclerotic cardiovascular disease. The Leqvio is the small entering RND that provide effective and sustained low-density lipoprotein cholesterol (LDL-C) reduction for patients with atherosclerotic cardiovascular disease (ACD).
In March 2019, Bristol-Myers Squibb Co. had entered into merger agreement under which it will acquire Celgene corp. for approximately $74 billion. Through this transaction the acquired company will lead to be one the specialty bio-pharma company that will be addressing patients suffering from, inflammatory and immunologic disease and cardiovascular disease through scientific capabilities along with high-value innovative medicines.
The Report Covers
- Market value data analysis of 2020 and forecast to 2027.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global cardiovascular drug market based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where in the market.
Table of Contents
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on the Global Cardiovascular Drug Industry
- Recovery Scenario of Global Cardiovascular Drug Industry
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of Covid-19 on Key Players
5.1.1. Anti-Clotting Agents
5.1.3. Calcium Channel Blockers
5.1.4. Renin-Angiotensin System Blockers
5.2. Global Cardiovascular Drugs Market by Disease Type
5.2.2. Coronary Artery Disease
5.2.5. Peripheral Artery Disease
5.3. Global Cardiovascular Drugs Market by Distribution Channel
5.3.1. Hospital Pharmacy
5.3.2. Online Pharmacy
5.3.3. Retail Pharmacy
6.1.1. United States
6.2.6. Rest of Europe
6.3.4. South Korea
6.3.5. Rest of Asia-Pacific
6.4. Rest of the World
7.3. Bayer AG
7.4. Boehringer Ingelheim International GmbH
7.5. Bristol-Myers Squibb Co.
7.6. Catalent, Inc
7.7. DAIICHI SANKYO CO., LTD.
7.9. F. HOFFMANN-LA ROCHE LTD.
7.10. Gilead Sciences, Inc.
7.11. GlaxoSmithKline plc.
7.12. Johnson & Johnson Services, Inc.
7.13. Probo Medical, LLC
7.14. Novartis AG
7.15. Merck & Co., Inc.
7.16. Otsuka Holdings Co., Ltd.
7.17. Pfizer Inc.
A selection of companies mentioned in this report includes:
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co.
- Catalent, Inc
- DAIICHI SANKYO CO., LTD.
- F. HOFFMANN-LA ROCHE LTD.
- Gilead Sciences, Inc.
- GlaxoSmithKline plc.
- Johnson & Johnson Services, Inc.
- Probo Medical, LLC
- Novartis AG
- Merck & Co., Inc.
- Otsuka Holdings Co., Ltd.
- Pfizer Inc.